Gravitor SR Tablet contains Pyridostigmine 180 mg, a cholinesterase inhibitor used primarily in the management of myasthenia gravis, a neuromuscular disorder characterized by muscle weakness and fatigue. Pyridostigmine works by inhibiting the enzyme acetylcholinesterase, thereby increasing the concentration of acetylcholine at the neuromuscular junction, which enhances communication between nerves and muscles and improves muscle strength. Gravitor SR is formulated as a sustained-release tablet to provide prolonged therapeutic effects, allowing for more consistent symptom control and improved patient compliance. It is indicated for symptomatic treatment of myasthenia gravis and may also be used in other conditions where enhanced cholinergic transmission is beneficial. The dosage should be individualized based on clinical response and tolerability, with careful monitoring for potential side effects such as gastrointestinal disturbances, excessive salivation, muscle cramps, or bradycardia. Contraindications include mechanical intestinal or urinary obstruction and known hypersensitivity to pyridostigmine. Caution is advised when used concomitantly with other cholinergic agents or in patients with asthma or cardiovascular disorders. Gravitor SR should be administered under medical supervision with regular assessment to optimize therapeutic outcomes and minimize adverse effects.